ClinicalTrials.gg
Active, not recruitingNCT04989946Updated Sep 30, 2026

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

A Phase 1/2 interventional study of Degarelix and pTVG-AR in Prostate Cancer, sponsored by University of Wisconsin, Madison. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Wisconsin, Madison · Phase 1/2, Interventional, and Treatment

How we know · 11 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison — 5 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · University of Wisconsin, Madison.

Enrollment
10th of 33
57 · median 30
Started
2021
the only one that year
Phase 1/2
3 of 38
none open now
Registered
32nd of 38
by date

Among the 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison, this one is the 10th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2021, is one of 3 in phase 1/2, and was the 32nd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Prostatic Neoplasms by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with T-cell checkpoint blockade, to induce and/or augment therapeutic T-cells following androgen deprivation in patients with newly diagnosed prostate cancer scheduled to undergo prostatectomy. Patients without evidence of metastatic disease, with tissue remaining from a pre-treatment biopsy, and who are being considered for standard treatment by prostatectomy, will be invited to participate and will be on study for up to 15 months.

Read the detailed description

The original design of this protocol was to examine the use of a plasmid DNA vaccine encoding Androgen Receptor (AR), alone or with nivolumab, to induce and/or augment therapeutic T-cells following androgen deprivation in participants with newly diagnosed prostate cancer scheduled to undergo prostatectomy in one of three treatment arms. Based on emerging preclinical data that the timing of PD-1 blockade with the first immunization may be critical, and that combining PD-1 and LAG-3 blockade can improve the anti-tumor efficacy of vaccination in murine models of prostate cancer, the trial was amended to include two additional treatment arms testing the timing of PD-1 blockade and the addition of LAG-3 blockade. All participants will receive treatment with degarelix for 8 weeks prior to prostatectomy. In the first part of the study encompassing the first 3 treatment arms, participants will be also be randomized to receive either no additional treatment, a DNA vaccine encoding AR, or a DNA vaccine encoding AR and nivolumab. The additional arms will randomize patients to receive cemiplimab (PD-1 antagonist) with vaccine or cemiplimab with fianlimab (LAG-3 antagonist) and vaccine, with each agent initiated with the first immunization.

Participants receiving vaccination will begin that treatment prior to degarelix, based on preclinical findings that this may be a preferred sequence of treatment. The overall goal is to determine whether a DNA vaccine can augment the number of prostate tumor-specific infiltrating CD8+ T cells elicited with androgen deprivation, and whether this might be further augmented by combination with T-cell checkpoint blockade.

Because these cells should have cytolytic effector function, the primary clinical endpoint is pathological response (pCR and secondarily MRD) at the time of prostatectomy. This endpoint was chosen based on observations from previous clinical trials evaluating androgen deprivation therapies alone in this setting.

Safety will also be a primary objective of the current study, as this vaccine and nivolumab have not been previously used in this early stage population. An additional secondary clinical endpoint will be 1-year PSA progression-free survival, after completion of all therapy, and with evidence of testosterone recovery.

Laboratory and correlative endpoints will include whether vaccination, with or without concurrent T-cell checkpoint blockade, elicits greater numbers of CD8+ tumor-infiltrating lymphocytes, and whether AR-specific prostate tissue-infiltrating CD8+ T cells and persistent systemic immunity are detectable after treatment with vaccination. Other correlative studies will evaluate FLT PET/CT (Arms 1-3) as an investigational means of specifically identifying tumor infiltration by proliferating T cells as an early marker of treatment response, and whether uptake in other normal tissues is associated with autoimmune toxicity. While this is a relatively small trial, given a focus on correlative endpoints, a phase 2 expansion design was chosen to further evaluate the safety and clinical efficacy if pathological responses are observed in the initial part of the trial. If pathological responses exceeding 20% are observed, this will be considered significantly different from what has been historically observed, and would justify proceeding with future larger studies evaluating these combination approaches in the neoadjuvant stage of prostate cancer.

[Per a protocol clarification letter approved 9/5/2025: Arm 2 was expanded to Phase 2 - adding 15 more participants per protocol]

Primary Objectives:

  1. To evaluate the safety of androgen deprivation and pTVG-AR DNA vaccine, alone or in combination with T-cell checkpoint blockade, in patients with newly diagnosed prostate cancer
  2. To determine if pathological complete responses or minimal residual disease (MRD) can occur in patients with prostate cancer treated with androgen deprivation and pTVG-AR, alone or in combination with T-cell checkpoint blockade, prior to definitive surgery

Secondary Clinical Objective:

  1. To estimate 1-year PSA progression-free survival (post-prostatectomy)
  2. To determine whether treatment with androgen deprivation and pTVG-AR DNA vaccine, alone or in combination with T-cell checkpoint blockade, leads to residual cancer burden (RCB) \<0.25 cm3 at the time of prostatectomy
  3. To determine the median progression-free survival

Laboratory / Correlative Objectives:

  1. To evaluate whether treatment with pTVG-AR elicits persistent systemic AR-specific Th1-biased T-cell responses
  2. To determine whether treatment with androgen deprivation and pTVG-AR elicits greater numbers of prostate tissue-infiltrating CD8+ T cells compared with androgen deprivation alone, and whether this is augmented with nivolumab, cemiplimab, or cemiplimab and fianlimab
  3. To determine if vaccination with pTVG-AR elicits AR-specific tumor-infiltrating CD8+ T cells
  4. To determine whether PD-1 +/- LAG-3 blockade treatment with androgen deprivation and vaccine increases the frequency of CD8+ T cells with memory and effector function, relative to exhausted phenotype, compared with androgen deprivation and vaccine alone
  5. To determine whether treatment elicits changes detectable by FLT PET imaging (Arms 1-3)
  6. To determine whether LAG-3 with PD-1 blockade and vaccination (Arm 5) elicits greater CD8 T cell infiltration compared to PD-1 blockade and vaccination alone (Arm 4)
  7. To determine whether prostate-tumor infiltrating T cells can be expanded and recognize AR
03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate
  • Patients must be considered candidates for prostatectomy as per standard of care
  • High-risk patients for recurrent disease, with high risk defined based on one of the following criteria:

    • Gleason score 7 and baseline serum prostate specific antigen (PSA) > 20 ng/mL
    • Gleason score > 7
  • of at least 12 months at screening
  • (ECOG) performance status of 0 or 1.
  • Adequate hematologic, renal and liver function as evidenced by the following within 4 weeks of day 1:

    • (ANC) > 1000 / mm3
    • HgB > 9.0 gm/dL independent of transfusion
    • > 100,000 / mm3
    • Creatinine \< 2.0 mg/dL
    • (AST), Alanine transaminase (ALT) \< 2.5 x institutional (ULN)
    • Total \< 2x institutional ULN (NOTE: in subjects with Gilbert's syndrome, if total bilirubin is >2x ULN, measure direct and indirect bilirubin and if direct bilirubin is within normal range, subject may be eligible)
  • No known history of 1 and 2, HTLV-1, or active or
  • Must have adequate tissue (ten 5µm unstained formalin-fixed paraffin-embedded (FFPE) sections containing prostate cancer) remaining from pre-treatment diagnostic prostate for research purposes
  • Patients must be willing to undergo large-volume blood draws (up to 200mL per time point) for the component of this trial
  • For those patients who are sexually active, they must be willing to use barrier methods during the period of treatment on this trial
  • Patients must be informed of the experimental nature of the study and its potential risks, and must sign an IRB-approved written form indicating such an
  • Ability to comply with all study procedures and willingness to remain supine for 120 minutes during imaging

Exclusion criteria

Exclusion Criteria:

  • Small cell or other variant (non-adenocarcinoma) prostate cancer histology
  • Prior treatment for prostate cancer, including androgen deprivation therapy (ADT), orchiectomy, antiandrogens, ketoconazole, abiraterone acetate or enzalutamide
  • Prior radiation to the prostate
  • Patients may not be receiving other agents or be receiving concurrent anticancer therapy other than the treatment-prescribed androgen deprivation therapy
  • Treatment with any of the following medications while on study is prohibited, not required except as indicated:

    • Systemic (at doses over the equivalent of 10 mg prednisone daily) - not permitted within 3 months of registration; inhaled, intranasal or topical corticosteroids are acceptable
    • PC-SPES
    • Herbal supplements that have been shown to modulate testosterone or androgen signaling (e.g. Saw Palmetto) are not allowed while on study
    • Megestrol
    • Ketoconazole
    • 5-α-reductase inhibitors - patients already taking 5-α-reductase inhibitors prior to 28 days prior to registration may stay on these agents throughout the course of therapy, but these should not be started while patients are on study
    • Diethylstilbesterol
    • Any other non-study hormonal agent or supplement being used with the intent of cancer treatment
  • Major surgery within 4 weeks of registration is prohibited
  • Active cardiac disease defined as active angina, symptomatic congestive heart failure, or myocardial infarction within 6 months of registration
  • Patients with known psychological or sociological conditions, addictive disorders or family problems, which would preclude compliance with the protocol
  • Patients who have undergone splenectomy
  • Patients must not have other active other than non-melanoma skin cancers or superficial bladder cancer (this includes any non-muscle invasive bladder cancer including Ta, CIS and T1), that have been adequately treated. Subjects with a history of other cancers who have been adequately treated and have been recurrence-free for > 3 years are eligible.
  • Any other medical intervention or condition, which, in the opinion of the principle investigator (PI) or treating physician, could compromise patient safety or adherence with the study requirements over the primary 3-6 month treatment period.
  • Patients who have concurrent enrollment on other phase I, II, or III investigational treatment studies cannot be actively receiving treatment and the last dose cannot be within 4 weeks.
  • Patients who have received a within 14 days prior to the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed
  • Patients with a history of life-threatening disease or active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Patients with a history of non-infectious pneumonitis that required corticosteroid treatment, or has current pneumonitis
  • Patients with a history of allergic reactions to the tetanus vaccine
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Active comparator
    Arm 1: Degarelix

    \- Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57

    Drug: Degarelix · Drug: FLT PET/CT

  • Experimental
    Arm 2: Degarelix and pTVG-AR

    * Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57 * pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71

    Drug: Degarelix · Biological: pTVG-AR · Drug: FLT PET/CT

  • Experimental
    Arm 3: Degarelix and pTVG-AR and Nivolumab

    * Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57 * pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71 * Nivolumab 240 mg IV administered at days 29, 43, 57 and 71

    Drug: Degarelix · Biological: pTVG-AR · Drug: Nivolumab · Drug: FLT PET/CT

  • Experimental
    Arm 4: Degarelix and pTVG-AR and Cemiplimab

    * Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57 * pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71 * Cemiplimab 350 mg IV administered at days 1, 22, 43 and 64

    Drug: Degarelix · Biological: pTVG-AR · Drug: Cemiplimab

  • Experimental
    Arm 5: Degarelix and pTVG-AR and Cemiplimab and Fianlimab

    * Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57 * pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71 * Cemiplimab 350 mg IV administered at days 1, 22, 43 and 64 * Fianlimab 1600 mg IV administered at days 1, 22, 43 and 64

    Drug: Degarelix · Biological: pTVG-AR · Drug: Cemiplimab · Drug: Fianlimab

Interventions

  • standard Gonadotropin-releasing hormone (GnRH) antagonist

  • BiologicalpTVG-AR

    DNA vaccine encoding androgen receptor ligand-binding domain

  • Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.

    Also known as: Opdivo

  • Cemiplimab is a human PD-1 blocking antibody approved for the treatment of patients with non-small cell lung cancer, cutaneous squamous cell carcinoma, and locally advanced basal cell carcinoma.

    Also known as: Libtavo

  • Lymphocyte activation gene-3 (LAG-3) is a protein that is upregulated on activated CD4+ and CD8+ T cells following T-cell receptor engagement. Binding of LAG-3 to MHC II on professional antigen-presenting cells suppresses the proliferation, activation, and cytokine secretion of T cells. Fianlimab is a human IgG4 antibody to lymphocyte activation gene-3 (LAG-3) that blocks LAG-3/MHC II-mediated T-cell inhibition.

    Also known as: REGN3767

  • DrugFLT PET/CT

    Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43

    Also known as: 3'-Deoxy-3'-[18F]Fluorothymidine (FLT) positron emission tomography (PET) /computed tomography (CT)

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response Rate (pCR)

    The pathological complete response will be estimated for each arm and reported along with the corresponding 95% confidence interval which will be constructed using the Wilson score method. Formal comparisons between arms will be conducted using Fisher's exact test. Participants in this study with unknown pathological response will be treated as non-responders in the primary analysis.

    Time frame: at prostatectomy (up to 3 months)

  2. Minimal Residual Disease (MRD) Rate

    The MRD rate will be estimated for each arm and reported along with the corresponding 95% confidence interval which will be constructed using the Wilson score method. Formal comparisons between arms will be conducted using Fisher's exact test. Participants in this study with unknown pathological response will be treated as non-responders in the primary analysis.

    Time frame: at prostatectomy (up to 3 months)

  3. Incidence of Adverse Events

    Adverse events will be evaluated using the most recent version of the Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: up to 15 months

  4. Toxicity Rates

    Toxicity rates (grade 2, grade 3, grade 4, grade ≥ 2, grade ≥ 3, etc.) will be calculated for each study arm and reported along the corresponding 95% confidence intervals. The 95% confidence intervals will be constructed using the Wilson score method.

    Time frame: up to 15 months

Secondary outcomes

  1. Progression-Free Survival (PSA) at 1-year

    Defined as a serum PSA \<0.2 ng/mL at 1 year after prostatectomy, in patients with non-castrate (\>25 ng/dL) testosterone levels.

    Time frame: up to 15 months on study (1 year after prostatectomy)

  2. Residual Cancer Burden (RCB)

    RCB will be determined using three-dimensional volume estimation based on the largest cross-sectional tumor dimension and number of cross-sections involved by tumor, corrected for tumor cellularity. The amount of RCB will be summarized for each arm in terms of medians and ranges. Comparisons between arms will be conducted using a nonparametric Wilcoxon rank sum test. Linear regression analysis will be conducted to evaluate whether AR-specific immune response is associated with RCB.

    Time frame: at prostatectomy (up to 3 months)

  3. Median Progression-Free Survival

    The median progression-free survival will be estimated for each arm using the Kaplan-Meier method and reported along with the corresponding two-sided 95% confidence intervals. The arm specific 95% confidence intervals for the median progression-free survival will be calculated using the Brookmeyer-Crowley method. Exploratory comparisons of progression-free survival between arms will be conducted using the log-rank test.

    Time frame: up to 39 months

Other outcomes

  1. Number of AR-specific Th1-biased T-cell responses

    Summarized in tabular format for each study arm. Fisher's exact test will be used to conduct the comparisons between arms.

    Time frame: up to 15 months on study (1 year after prostatectomy)

  2. Change in levels of prostate tissue-infiltrating CD8+T cells

    Changes in these levels from the baseline to mid-treatment and post-treatment assessments will be evaluated within each arm using a paired t-test.

    Time frame: baseline, month 3

  3. Change in levels of AR-specific tumor-infiltrating CD8+T cells

    Changes in these levels from the baseline to mid-treatment and post-treatment assessments will be evaluated within each arm using a paired t-test.

    Time frame: baseline, month 3

  4. Frequency of CD8+ T cells with memory and effector function

    The frequency of CD8+ T cells with memory and effector function will be analyzed and compared between study arms using a generalized linear mixed effects model with subject specific random effects.

    Time frame: up to 15 months on study (1 year after prostatectomy)

  5. FLT-PET imaging endpoints: SUVmean

    3'-Deoxy-3'-\[18F\]Fluorothymidine (FLT) positron emission tomography (PET)/computed tomography (CT) endpoints include mean Standardized Update Value (SUVmean).

    Time frame: baseline and day 45

  6. FLT-PET imaging endpoints: SUVmax

    Time frame: baseline and day 45

  7. FLT-PET imaging endpoints: SUVtotal

    Time frame: baseline and day 45

07

Study locations

1 site
08

References and documents

Publications

  • Jarrard D, Eickhoff J, Kyriakopoulos CE, Jeon D, Tonelli TP, Johnson L, Huang W, McNeel DG. Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer. J Immunother Cancer. 2026 Mar 4;14(3):e013790. doi: 10.1136/jitc-2025-013790. PubMed 41781018 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 114 non-industry phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's planned 60 months is close to that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2021
First posted
Aug 4, 2021
StartActual
Dec 16, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: contact details
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04989946
Collaborators
United States Department of Defense, Regeneron Pharmaceuticals, Bristol-Myers Squibb, National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Aug 4, 2021
Start date
Dec 16, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Douglas McNeel, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion